Search

for
Search:

Did you mean Phosphodiesterase Inhibitors?

GlossaryPhosphodiesterase Inhibitors

block enzymes that break down cyclic nucleotides

Phosphodiesterase Inhibitors (PDE Inhibitors or PDEIs) are a class of drugs that block the action of phosphodiesterase enzymes, which are responsible for breaking down cyclic nucleotides like cAMP and cGMP. By inhibiting these enzymes, PDE inhibitors can increase the levels of these cyclic nucleotides, leading to various therapeutic effects such as vasodilation, anti-inflammatory actions, and improved cardiac function. These drugs are used to treat conditions like erectile dysfunction, pulmonary hypertension, and certain types of heart failure.

Related Terms

Sort by

Research

30 / 634 results

research PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION

April 2018 in “The Journal of Urology”

Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.

research Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions

January 2018 in “Springer eBooks”

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors

research Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors

12 citations , December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

The Effect of Cilostazol, a Phosphodiesterase 3 (PDE3) Inhibitor, on Human Hair Growth with Dual Promoting Mechanisms

research The effect of cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, on human hair growth with the dual promoting mechanisms

21 citations , April 2018 in “Journal of Dermatological Science”

Cilostazol helps hair grow by making hair root cells grow faster and changing growth factor levels.

research Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata

10 citations , August 2019 in “European Journal of Dermatology”

The document did not conclude on apremilast's effectiveness for severe alopecia areata.

research The effects of phosphodiesterase 3 (PDE3) inhibitor on hair follicle cell viability and hair growth

1 citations , January 2020 in “Seoul National University Open Repository (Seoul National University)”

PDE3 inhibitor may help treat hair loss by promoting hair growth.

research Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review

9 citations , December 2020 in “Dermatologic Therapy”

Certain drugs are effective for skin conditions like psoriasis, vitiligo, and hair loss.

research The use of phosphodiesterase inhibitors for the treatment of alopecia

3 citations , April 2019 in “Journal of Dermatological Treatment”

Caffeine shows promise for treating some types of hair loss, but more research is needed.

research Comment on ‘Androgenetic alopecia is associated with increased scalp hardness’: role of phosphodiesterase inhibitors?

1 citations , April 2020 in “Journal of The European Academy of Dermatology and Venereology”

Drugs like PDEI may help hair disorders like AGA.

research Phosphodiesterase inhibitors used in androgenic alopecia as a possible risk factor for testicular tumor

April 2023 in “Medicina Clínica (english Edition)”

research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)

March 2026 in “Figshare”

These medications for BPH have known risks and may have new side effects.

research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)

March 2026 in “Figshare”

These medications for BPH have known risks and may have new side effects.

research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)

March 2026 in “The Aging Male”

PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.

research 5-Alpha-Reductase Inhibitors and Combination Therapy

15 citations , July 2016 in “Urologic Clinics of North America”

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

research FDA approves label addition for PDE-5 inhibitor

October 2013 in “Urology Times eNews”

The FDA approved using Cialis with Proscar for better treatment options.

research 570 Targeting phosphodiesterase 8A (PDE8A) to boost adipogenesis and hair regeneration

July 2024 in “Journal of Investigative Dermatology”

Inhibiting PDE8A may help treat hair loss by boosting fat cell growth and hair regeneration.

Sexual Dysfunction Related to Drugs: A Critical Review. Part V: Alpha-Blocker and 5-ARI Drugs

research Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs

15 citations , November 2015 in “Pharmacopsychiatry”

α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.

research Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis

8 citations , July 2024 in “Journal of Advanced Research”

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

research Investigation, treatment and monitoring of late‐onset hypogonadism in males: ISA, ISSAM, and EAU recommendations

280 citations , May 2005 in “Andrology”

Testosterone treatment for older men can have short-term benefits, but long-term risks are unclear, requiring careful evaluation and monitoring.

Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

research Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

35 citations , May 2020 in “Frontiers in Pharmacology”

Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.

research Risks and side effects in the medical management of benign prostatic hyperplasia

26 citations , December 2023 in “Prostate International”

Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.

research Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review

1 citations , December 2023 in “Curēus”

Tadalafil is effective for treating urinary symptoms in men with BPH.

research Wider clinical applications of fumaric acid esters: A useful option in psoriasis patients with multiple sclerosis

1 citations , May 2015 in “Journal of The American Academy of Dermatology”

Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.

research Medical management of benign prostatic hyperplasia

March 2024 in “Cleveland Clinic journal of medicine”

Alpha-blockers and 5-alpha reductase inhibitors are main treatments for BPH, with new support for phosphodiesterase-5 inhibitors and beta-3 agonists.

Search

for
Search:

Related Terms

Research

research PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION

research Phosphodiesterase (PDE) Inhibitors for the Treatment of Inflammatory Skin Conditions

research Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase‐4 inhibitors

research The effect of cilostazol, a phosphodiesterase 3 (PDE3) inhibitor, on human hair growth with the dual promoting mechanisms

research Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata

research The effects of phosphodiesterase 3 (PDE3) inhibitor on hair follicle cell viability and hair growth

research Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review

research The use of phosphodiesterase inhibitors for the treatment of alopecia

research Comment on ‘Androgenetic alopecia is associated with increased scalp hardness’: role of phosphodiesterase inhibitors?

research Phosphodiesterase inhibitors used in androgenic alopecia as a possible risk factor for testicular tumor

research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)

research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)

research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)

research 5-Alpha-Reductase Inhibitors and Combination Therapy

research FDA approves label addition for PDE-5 inhibitor

research 570 Targeting phosphodiesterase 8A (PDE8A) to boost adipogenesis and hair regeneration

research Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs

research Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis

research Investigation, treatment and monitoring of late‐onset hypogonadism in males: ISA, ISSAM, and EAU recommendations

research Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

research Risks and side effects in the medical management of benign prostatic hyperplasia

research Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review

research Wider clinical applications of fumaric acid esters: A useful option in psoriasis patients with multiple sclerosis

research Medical management of benign prostatic hyperplasia

research Platelet-Rich Plasma for Urologic Conditions: An Early Call for Composition Reporting

research Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice

research Treatment of actinic cheilitis with ingenol mebutate gel: Experience in four patients

research Study of QuantiFERON’S conversion/reversal phenomena in patients with psoriasis during biological treatment

research 8 Finasteride-Associated Suicide and Depression in Men Treated for Hypogonadism and Impotence

research Evaluation of risk of SSRI-associated impotence and low libido in men exposed to finasteride